Phase 2
Completed N=51
Ziprasidone in the Psychosis Prodrome
Psychosis Prodrome
Source: ClinicalTrials.gov NCT00635700 ↗
Enrolled (actual)
51
Serious AEs
0.0%
Results posted
Oct 2016
Primary outcomePrimary: Conversion to Psychosis — 1; 2 participants
Summary
This study aims to determine whether ziprasidone is superior to placebo over 24 weeks for patients with the psychosis prodrome.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Conversion to Psychosis |
1; 2 | — |
| SECONDARY Change in Scale of Psychosis-risk Symptoms Total Score |
-0.271; 0 | — |
Eligibility Criteria
Inclusion Criteria
- Structured Interview for Psychosis-risk Syndromes criteria for Clinical High Risk for Psychosis
- clinically referred
Exclusion Criteria
- prolonged corrected QT interval
- history of syncope
Data sourced from ClinicalTrials.gov (NCT00635700). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.